Data gathered: January 2
Alternative Data for Stoke Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 795 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,531 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 85 | Sign up | Sign up | Sign up |
| Linkedin Employees | 136 | Sign up | Sign up | Sign up |
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
| Price | $11.57 |
| Target Price | Sign up |
| Volume | 90,800 |
| Market Cap | $584M |
| Year Range | $10.8 - $17.52 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Geode Capital Management LLC Purchases 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)January 1 - ETF Daily News |
|
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 2.9% – Here’s What HappenedDecember 26 - ETF Daily News |
 |
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDexDecember 25 - Yahoo |
 |
Stoke Therapeutics (NASDAQ:STOK) Research Coverage Started at Chardan CapitalDecember 23 - ETF Daily News |
|
Jane Street Group LLC Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)December 19 - ETF Daily News |
 |
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In GrowthDecember 16 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 4.9M | 13M | -7.8M | -26M | -30M | -0.469 |
| Q2 '24 | 4.8M | 13M | -8.2M | -26M | -28M | -0.460 |
| Q1 '24 | 4.2M | 10M | -6M | -26M | -27M | -0.570 |
| Q4 '23 | 2.8M | 11M | -7.8M | -27M | -28M | -0.600 |
| Q3 '23 | 3.3M | 10M | -7M | -25M | -27M | -0.550 |
Insider Transactions View All
| Blue Horizon Enterprise Ltd filed to sell 6,906,181 shares at $11.5. December 27 '24 |
| Kaye Edward M. MD filed to sell 61,885 shares at $13. December 11 '24 |
| Allan Jonathan filed to sell 21,476 shares at $13. December 11 '24 |
| Ticho Barry filed to sell 44,746 shares at $13. December 11 '24 |
| Allan Jonathan filed to sell 23,028 shares at $13.7. December 11 '24 |
Similar companies
Read more about Stoke Therapeutics (STOK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Stoke Therapeutics?
The Market Cap of Stoke Therapeutics is $584M.
What is the current stock price of Stoke Therapeutics?
Currently, the price of one share of Stoke Therapeutics stock is $11.57.
How can I analyze the STOK stock price chart for investment decisions?
The STOK stock price chart above provides a comprehensive visual representation of Stoke Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Stoke Therapeutics shares. Our platform offers an up-to-date STOK stock price chart, along with technical data analysis and alternative data insights.
Does STOK offer dividends to its shareholders?
As of our latest update, Stoke Therapeutics (STOK) does not offer dividends to its shareholders. Investors interested in Stoke Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Stoke Therapeutics?
Some of the similar stocks of Stoke Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.